BioCryst presents new Orladeyo (berotralstat) data at 7th Bradykinin Symposium BioCryst Pharmaceuticals today announced the presentation of six...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Rubriques :
Maroc - HAEI.ORG - A La Une - 06/Sep 18:54
KalVista Presents Sebetralstat Data at Bradykinin Symposium 2024
KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024 KalVista Pharmaceuticals announced that it presented additional analyses of the efficacy and safety of sebetralstat from phase 2 and phase 3 double-blind, placebo-controlled crossover clinical trials as well as interim data from KONFIDENT-S, a phase 3 open-label extension trial, and real-world patient data at the [...]
Articles similaires
Pharvaris presents data at the Bradykinin Symposium 2024
haei.org - 05/Sep 18:46
Pharvaris presents data at the Bradykinin Symposium 2024 Pharvaris announced a summary of data being presented at the ongoing 7th Bradykinin...
Pharvaris presents deucrictibant long-term extension data for both the prophylactic and on-demand treatment of HAE at the Bradykinin Symposium 2024
haei.org - 05/Sep 18:45
Pharvaris presents deucrictibant long-term extension data for both the prophylactic and on-demand treatment of HAE at the Bradykinin Symposium 2024...
KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema
drugs.com - 03/Sep 20:09
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Sep. 3, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the U.S....
KalVista announces FDA acceptance of NDA for sebetralstat for oral on-demand treatment of HAE
haei.org - 03/Sep 17:29
KalVista announces FDA acceptance of New Drug Application for sebetralstat for oral on-demand treatment of hereditary angioedema KalVista...
Cytovation to present safety and efficacy data from CICILIA phase I/IIa clinical trial evaluating CY─101 in solid tumors
pharmabiz.com - 01:13
Cytovation ASA, a clinical stage oncology company focused on the development of its first─in─class bifunctional immunotherapy CY─101 (CyPep─1)...
Relief Therapeutics presents PKU GOLIKE study results at SSIEM 2024
pharmabiz.com - 03/Sep 00:00
Relief Therapeutics Holding SA, a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare...
Les derniers communiqués
-
Aucun élément